Barclays PLC Halozyme Therapeutics, Inc. Call Options Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2019 Feb 10, 2020	SELL	$14.93 - $19.53 $49,269 - $64,449	-3,300 Reduced 18.13%	14,900 $264,000
Q3 2019 Nov 14, 2019	SELL	$15.2 - $17.69 $31,920 - $37,149	-2,100 Reduced 10.34%	18,200 $282,000
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $193,225 - $226,106	13,100 Added 181.94%	20,300 $348,000
Q1 2019 May 15, 2019	BUY	$13.94 - $17.58 $44,608 - $56,255	3,200 Added 80.0%	7,200 $116,000
Q4 2018 Feb 14, 2019	SELL	$13.33 - $18.66 $842,456 - $1.18 Million	-63,200 Reduced 94.05%	4,000 $59,000
Q1 2018 May 15, 2018	BUY	$17.06 - $21.2 $1.11 Million - $1.38 Million	65,200 Added 3260.0%	67,200 $1.32 Million
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $33,500 - $41,600	2,000	2,000 $41,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.57B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.